Hospitals and doctors stay mum on drug pricing negotiation; what insurers are doing about naloxone for overdoses

Taking stock of the drug industry, from the lab to the medicine chest

August 31, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | As pharmaceutical companies bemoan Medicare's drug negotiations, hospitals and doctors stay mum As pharmaceutical companies are bemoaning Medicare's drug negotiations, hospitals and doctors are staying mum. By Bob Herman A big insurer decides to cover naloxone for overdose; will others follow? Blue Cross Blue Shield of Massachusetts will cover the over-the-counter formulation. Experts say more needs to be done to expand access. By Lev Facher STAT+ | Drug firms test medicines to halt Alzheimer's before symptoms appear Researchers are testing an intravenous drug they hope will prevent the onset of symptoms, or at least delay them. By Jonathan Saltzman — Boston Globe Adobe STAT+ | Sly CAR-T strategy evades 'fratricide' problem to aim at all blood cancers A study in mice uses base editing to render healthy blood cells invisible to engineered cancer-killing T cells. By Jason Mast

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser